Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch and Blue Shield of California sign first ever comprehensive agreement for its monitoring services (with document)

Un document

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
Contracts/LifeWatch AG

10.01.2012

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless remote cardiac and medical patient monitoring service
provider in the U.S., today reports that it has successfully negotiated its
first ever contract for its NiteWatch and core cardiac monitoring services with
the insurance company Blue Shield of California which covers 3.4 million lives.
This insurer is one of the independent licensees of the BlueCross BlueShield
Association whose licensees cover every state in America.

You will find a PDF-version of this press release at the end of this message.

Acceptance of the NiteWatch Home Sleep Testing service for diagnosing
obstructive sleep apnea (OSA) is steadily on the rise in the U.S. healthcare
market, and in California particularly. LifeWatch has been able to demonstrate
to Blue Shield of California, an important regional West Coast carrier, the
advantages of the NiteWatch service. Patients insured by Blue Shield of
California will now receive coverage for the NiteWatch service and our core
cardiac monitoring services, including ACT cardiac telemetry services for their
Medicare Advantage patients.

Blue Shield of California, located in San Francisco, California, partners with
around 65,000 physicians across the entire State and covers approximately 3.4
million patients. The Californian not-for-profit mutual benefit corporation is
independently owned and operates as a licensee of the BlueCross BlueShield
Association (www.bcbs.com). Blue Shield of California is widely recognized as
an innovative carrier and received 3 out of 4 stars in Meeting National Care
Standards, as published by the California Healthcare Quality Report Card 2011
Edition.

In February 2011 LifeWatch opened its third call center in San Francisco,
California, in order to better penetrate the attractive West Coast healthcare
market. After convincing the Heritage Provider Network in California (see press
release from 05/10/2011) LifeWatch gains another important West Coast carrier
for its monitoring services and further enforces the importance of the West
Coast call center. The agreement takes effect retroactively from November 15,
2011.

The NiteWatch service is designed to diagnose OSA, which is characterized by
the temporary suspension of breathing during sleep. OSA is associated with an
increased risk of cardiovascular disease, stroke, high blood pressure,
arrhythmia, diabetes, and many serious accidents due to fatigue and sleepiness.
An estimated 38 million individuals in the U.S. suffer from OSA yet less than
one out of seven have been diagnosed correctly. Failure to diagnose is in part
due to the fact that patients are required to perform the test in a sleep lab,
which frequently have long wait times for lab rooms. Patients are also
discomforted by sleeping in a strange environment, which can often adversely
affect test results. Due to the growing recognition of the need for home sleep
testing as a bona fide alternative to sleep labs, the NiteWatch Home Sleep
Testing service is becoming a diagnostic solution for many payors. Medicare
already decided in January 2009 to provide coverage for the Home Sleep Testing
Service.

"Once Medicare decided to provide coverage for Home Sleep Testing in early
2009, private insurance companies began to follow suit. Now Blue Shield of
California, an important West Coast carrier, has recognized the benefits of the
NiteWatch service. The opening of our third call center in San Francisco,
California, was an important strategic step in expanding our services to the
West Coast." said Dr. Yacov Geva, Chairman and CEO of LifeWatch AG. "Furthermore
our NiteWatch service will contribute to better quality of life for our patients
thanks to earlier and more accurate detection which enables more appropriate
treatment options." He also noted the inclusion of the company´s core cardiac
monitoring services, including the industry leading ACT telemetry monitor, was
yet another indication of the importance of LifeWatch´s services to those
populations serviced by Blue Shield of CA.


About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote
patient monitoring services. LifeWatch services cater to individuals, ranging
from high-risk and chronically ill patients, to consumers of health and
wellness products. LifeWatch has subsidiaries in the United States, the
Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is
the parent company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology products.
LifeWatch is also introducing a new program for Home Sleep Testing of
Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For
additional information, please visit www.lifewatch.com.

Sign-up for customized email alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are forward-
looking statements. The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended to
identify forward-looking statements. LifeWatch AG has based these forward-
looking statements largely on current expectations and projections about future
events and financial trends that it believes may affect the financial condition,
results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the forward-
looking statements. All forward-looking statements are based only on data
available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/NLkgQKzC

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/NLkgQKzC


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: Open Market / XETRA: Frankfurt, free trade: Berlin, Main Standard:
             SIX Swiss Exchange 
language:   English

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG